Amgen 2006 Annual Report Download - page 3

Download and view the complete annual report

Please find page 3 of the 2006 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

* Defined as the cumulative number of years of treatment for all
ENBREL patients, calculated by multiplying the number of patients
on ENBREL by their individual times on therapy.
Joe Carlin of Cary, North Carolina,
takes Enbrel® (etanercept) to help
control his severe plaque psoriasis.
ENBREL has made a difference
in the lives of people coping with
moderate-to-severe rheumatoid
arthritis, moderate-to-severe juvenile
rheumatoid arthritis, psoriatic arthritis,
ankylosing spondylitis and moderate-
to-severe plaque psoriasis. In 2006,
Amgen observed a remarkable
milestone: one million patient-years
of experience* with ENBREL.